Greg Ball

Greg’s practice covers a range of technologies in biotechnology, with a particular focus on vaccines, therapeutic antibodies and antisense compounds.  His work involves all aspects of patent prosecution at the EPO including attacking and defending patents in post-grant opposition and appeal. He is experienced in coordinating prosecution of complex global patent portfolios, and focuses on providing strategic advice that is tailored to the client’s commercial goals.  This experience also extends to management of European SPC portfolios.

Greg joined Carpmaels & Ransford as a trainee patent attorney in September 2013. He has a degree in Molecular and Cellular Biochemistry from Oxford University.  During his final year project he identified a deafness-causing mutation in a mutant mouse line, which led to a publication in the Journal of Neuroscience.

After graduating, Greg continued working in the deafness field, initially as a researcher at the Medical Research Council’s Mammalian Genetics Unit, before moving to University College London’s Ear Institute to undertake a PhD in Auditory Cell Biology. His doctoral thesis focused on the cell biology underlying deafness and hearing loss, specifically the role of extracellular regulated kinase signalling in sensory cell death.

During his PhD, Greg was awarded a Bogue Research Fellowship, allowing him to broaden his research experience at the National Institutes of Health in the US, where his work focused on viral-mediated gene delivery to cells of the inner ear. He also enjoyed keeping up-to-date with the latest advances in stem cell research in his role as a writer for the Progress Educational Trust’s BioNews newsletter.